Not good here if true:
Nomura Financial Advisory and Securities in its latest pharmaceuticals sector research report has commented on expected catalysts from US market for pharma companies. The same is as follows:
Dr. Reddy`s Lab - Buy
DRRD`s US prescriptions were up +33.2% y-y in August 2011.
DRRD has been able to garner 7.4% market share in generic Arixtra (USD 340 million), while the Apotex (AG) has 62.7% market share for the week ended 23 September 2011. This is a negative surprise as we were expecting a market share of 30-40% for DRRD. The management expects gradual market share gains as production yields improve.
http://www.myiris.com/newsCentre/storyShow.php?fileR=20111012132606199&dir=2011/10/12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable